201 related articles for article (PubMed ID: 37121094)
1. Longitudinal relationship between the gut microbiota variation and diversity and gut graft-versus-host disease (GVHD) following pediatric allogeneic hematopoietic cell transplantation (HCT) - Case series.
Gray AN; Tobin NH; Moore TB; Li F; Aldrovandi GM
Int J Med Microbiol; 2023 May; 313(3):151580. PubMed ID: 37121094
[TBL] [Abstract][Full Text] [Related]
2. Allogeneic hematopoietic cell transplantation, the microbiome, and graft-versus-host disease.
van Lier YF; Vos J; Blom B; Hazenberg MD
Gut Microbes; 2023; 15(1):2178805. PubMed ID: 36794370
[TBL] [Abstract][Full Text] [Related]
3. The impact of intestinal microbiota in antithymocyte globulin-based myeloablative allogeneic hematopoietic cell transplantation.
Gu Z; Xiong Q; Wang L; Wang L; Li F; Hou C; Dou L; Zhu B; Liu D
Cancer; 2022 Apr; 128(7):1402-1410. PubMed ID: 35077579
[TBL] [Abstract][Full Text] [Related]
4. Stool Microbiota at Neutrophil Recovery Is Predictive for Severe Acute Graft vs Host Disease After Hematopoietic Cell Transplantation.
Golob JL; Pergam SA; Srinivasan S; Fiedler TL; Liu C; Garcia K; Mielcarek M; Ko D; Aker S; Marquis S; Loeffelholz T; Plantinga A; Wu MC; Celustka K; Morrison A; Woodfield M; Fredricks DN
Clin Infect Dis; 2017 Nov; 65(12):1984-1991. PubMed ID: 29020185
[TBL] [Abstract][Full Text] [Related]
5. Microbiome: An Emerging New Frontier in Graft-Versus-Host Disease.
Kumari R; Palaniyandi S; Hildebrandt GC
Dig Dis Sci; 2019 Mar; 64(3):669-677. PubMed ID: 30523482
[TBL] [Abstract][Full Text] [Related]
6. Fecal Microbiota Transplantation for Acute Graft-versus-Host Disease after Allogeneic Hematopoietic Cell Transplantation: Expanding the Horizon into Pediatrics.
Gray AN; DeFilipp Z
Transplant Cell Ther; 2023 Aug; 29(8):484-491. PubMed ID: 37169290
[TBL] [Abstract][Full Text] [Related]
7. Fecal microbiota transfer for refractory intestinal graft-versus-host disease - Experience from two German tertiary centers.
Goeser F; Sifft B; Stein-Thoeringer C; Farowski F; Strassburg CP; Brossart P; Higgins PG; Scheid C; Wolf D; Holderried TAW; Vehreschild MJGT; Cruz Aguilar MR
Eur J Haematol; 2021 Aug; 107(2):229-245. PubMed ID: 33934412
[TBL] [Abstract][Full Text] [Related]
8. Microbiome and diversity indices during blood stem cells transplantation - new perspectives?
Parco S; Benericetti G; Vascotto F; Palmisciano G
Cent Eur J Public Health; 2019 Dec; 27(4):335-339. PubMed ID: 31951695
[TBL] [Abstract][Full Text] [Related]
9. The intestinal microbiota in allogeneic hematopoietic cell transplant and graft-versus-host disease.
Staffas A; Burgos da Silva M; van den Brink MR
Blood; 2017 Feb; 129(8):927-933. PubMed ID: 27940475
[TBL] [Abstract][Full Text] [Related]
10. A Fructo-Oligosaccharide Prebiotic Is Well Tolerated in Adults Undergoing Allogeneic Hematopoietic Stem Cell Transplantation: A Phase I Dose-Escalation Trial.
Andermann TM; Fouladi F; Tamburini FB; Sahaf B; Tkachenko E; Greene C; Buckley MT; Brooks EF; Hedlin H; Arai S; Mackall CL; Miklos D; Negrin RS; Fodor AA; Rezvani AR; Bhatt AS
Transplant Cell Ther; 2021 Nov; 27(11):932.e1-932.e11. PubMed ID: 34274493
[TBL] [Abstract][Full Text] [Related]
11. A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
Ramalingam S; Siamakpour-Reihani S; Bohannan L; Ren Y; Sibley A; Sheng J; Ma L; Nixon AB; Lyu J; Parker DC; Bain J; Muehlbauer M; Ilkayeva O; Kraus VB; Huebner JL; Spitzer T; Brown J; Peled JU; van den Brink M; Gomes A; Choi T; Gasparetto C; Horwitz M; Long G; Lopez R; Rizzieri D; Sarantopoulos S; Chao N; Sung AD
PLoS One; 2021; 16(6):e0252995. PubMed ID: 34170918
[TBL] [Abstract][Full Text] [Related]
12. Healthcare resource utilization and costs associated with acute graft-versus-host disease following allogeneic hematopoietic cell transplantation.
Yu J; Lal L; Anderson A; DuCharme M; Parasuraman S; Weisdorf D
Support Care Cancer; 2020 Nov; 28(11):5491-5499. PubMed ID: 32172407
[TBL] [Abstract][Full Text] [Related]
13. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
14. Impact of decontamination therapy on gastrointestinal acute graft-versus-host disease after allogeneic hematopoietic cell transplantation in children: Decontamination therapy in allo-HCT.
Gałązka P; Styczyński J; Czyżewski K; Salamonowicz-Bodzioch M; Frączkiewicz J; Zając-Spychała O; Zaucha-Prażmo A; Goździk J; Biliński J; Basak GW
Curr Res Transl Med; 2021 Jul; 69(3):103298. PubMed ID: 34144374
[TBL] [Abstract][Full Text] [Related]
15. Gut microbiome in allogeneic hematopoietic stem cell transplantation and specific changes associated with acute graft
Le Bastard Q; Chevallier P; Montassier E
World J Gastroenterol; 2021 Dec; 27(45):7792-7800. PubMed ID: 34963742
[TBL] [Abstract][Full Text] [Related]
16. How does transfusion-associated graft-versus-host disease compare to hematopoietic cell transplantation-associated graft-versus-host disease?
Aizawa K; Peltier D; Matsuki E; Toubai T
Transfus Apher Sci; 2022 Apr; 61(2):103405. PubMed ID: 35210194
[TBL] [Abstract][Full Text] [Related]
17. [Gut microbiota and graft-versus-host disease: broad-spectrum antibiotic use increases post-allogeneic hematopoietic stem cell transplant graft-versus-host disease-related mortality].
Shono Y
Rinsho Ketsueki; 2017; 58(7):835-842. PubMed ID: 28781282
[TBL] [Abstract][Full Text] [Related]
18. Microbiota long-term dynamics and prediction of acute graft-versus-host disease in pediatric allogeneic stem cell transplantation.
Ingham AC; Kielsen K; Mordhorst H; Ifversen M; Aarestrup FM; Müller KG; Pamp SJ
Microbiome; 2021 Jun; 9(1):148. PubMed ID: 34183060
[TBL] [Abstract][Full Text] [Related]
19. A Promising Insight: The Potential Influence and Therapeutic Value of the Gut Microbiota in GI GVHD.
Li J; Zhang X; Chen Y; Zheng Q; Zhao M; Jiang H
Oxid Med Cell Longev; 2022; 2022():2124627. PubMed ID: 35571252
[TBL] [Abstract][Full Text] [Related]
20. [GVHD: pathophysiology and novel agents].
Ara T; Hashimoto D
Rinsho Ketsueki; 2022; 63(9):1261-1269. PubMed ID: 36198552
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
